London, United Kingdom / 23.05.2022 10:31:00
This Monday, the vaccine against covid-19 Vaxzevria, from the British pharmaceutical laboratory AstraZeneca, was approved in a third dose for adults in the European Union (EU).
“Healthcare professionals can now use Vaxzevria as a third dose in patients who previously received doses of Vaxzevria or an EU-approved messenger RNA vaccine,” Astrazeneca said.
The European Medicines Agency (EMA) gave the authorization on Monday “after a set of tests demonstrating an increase in the immune response after a third dose of Vaxzevria”consecutive to two doses of the Astrazeneca vaccine or another approved by the EU, according to a statement on the agency’s website.
The vaccine created in collaboration with the University of Oxford has not been chosen by the British government for its booster campaign — it primarily proposes Pfizer and Moderna vaccines — despite being one of the first on the market in the UK, where it was the majority chosen for the first two doses.
Vaxzevria is however a possible option for people who have already received his first two doses in the UK.